ABSTRACT
Background: Up to 50-60% of patients with diabetes have non-diabetic kidney disease (NDKD) on kidney biopsy. Diabetic retinopathy (DR) is a microvascular complication of diabetes frequently associated with diabetic nephropathy (DN). The objective of the current study was to investigate the kidney outcomes and survival in patients with biopsy diagnoses of DN and NDKD according to the presence of DR. Methods: We conducted an observational, multicentre and retrospective study of the pathological findings of renal biopsies from 832 consecutive patients with diabetes from 2002 to 2014 from 18 nephrology departments. The association of DR with kidney replacement therapy (KRT) or survival was assessed by Kaplan-Meier and Cox regression analyses. Results: Of 832 patients with diabetes and renal biopsy, 768 had a retinal examination and 221/768 (22.6%) had DR. During a follow-up of 10 years, 288/760 (37.9%) patients with follow-up data needed KRT and 157/760 (20.7%) died. The incidence of KRT was higher among patients with DN (alone or with NDKD) and DR [103/175 (58.9%)] than among patients without DR [88/216 (40.7%), P < .0001]. The incidence of KRT was also higher among patients with only NDKD and DR than among those without DR [18/46 (39.1%) versus 79/331 (23.9%), P < .0001]. In multivariate analysis, DR or DN were independent risk factors for KRT {hazard ratio [HR] 2.48 [confidence interval (CI) 1.85-3.31], P < .001}. DN (with or without DR) was also identified as an independent risk factor for mortality [HR 1.81 (CI 1.26-2.62), P = .001]. Conclusions: DR is associated with a higher risk of progression to kidney failure in patients with histological DN and in patients with NDKD.
ABSTRACT
BACKGROUND: Diabetic patients with kidney disease have a high prevalence of non-diabetic renal disease (NDRD). Renal and patient survival regarding the diagnosis of diabetic nephropathy (DN) or NDRD have not been widely studied. The aim of our study is to evaluate the prevalence of NDRD in patients with diabetes and to determine the capacity of clinical and analytical data in the prediction of NDRD. In addition, we will study renal and patient prognosis according to the renal biopsy findings in patients with diabetes. METHODS: Retrospective multicentre observational study of renal biopsies performed in patients with diabetes from 2002 to 2014. RESULTS: In total, 832 patients were included: 621 men (74.6%), mean age of 61.7 ± 12.8 years, creatinine was 2.8 ± 2.2 mg/dL and proteinuria 2.7 (interquartile range: 1.2-5.4) g/24 h. About 39.5% (n = 329) of patients had DN, 49.6% (n = 413) NDRD and 10.8% (n = 90) mixed forms. The most frequent NDRD was nephroangiosclerosis (NAS) (n = 87, 9.3%). In the multivariate logistic regression analysis, older age [odds ratio (OR) = 1.03, 95% CI: 1.02-1.05, P < 0.001], microhaematuria (OR = 1.51, 95% CI: 1.03-2.21, P = 0.033) and absence of diabetic retinopathy (DR) (OR = 0.28, 95% CI: 0.19-0.42, P < 0.001) were independently associated with NDRD. Kaplan-Meier analysis showed that patients with DN or mixed forms presented worse renal prognosis than NDRD (P < 0.001) and higher mortality (P = 0.029). In multivariate Cox analyses, older age (P < 0.001), higher serum creatinine (P < 0.001), higher proteinuria (P < 0.001), DR (P = 0.007) and DN (P < 0.001) were independent risk factors for renal replacement therapy. In addition, older age (P < 0.001), peripheral vascular disease (P = 0.002), higher creatinine (P = 0.01) and DN (P = 0.015) were independent risk factors for mortality. CONCLUSIONS: The most frequent cause of NDRD is NAS. Elderly patients with microhaematuria and the absence of DR are the ones at risk for NDRD. Patients with DN presented worse renal prognosis and higher mortality than those with NDRD. These results suggest that in some patients with diabetes, kidney biopsy may be useful for an accurate renal diagnosis and subsequently treatment and prognosis.
ABSTRACT
Background: Frailty is an aging-associated state of increased vulnerability, which raises the risk of adverse outcomes. Chronic kidney disease is associated with higher prevalence of frailty. Our aim was to estimate frailty prevalence in a hemodialysis population and its influence on short-term outcomes. Design: Observational prospective longitudinal study of 277 prevalent hemodialysis patients. Frailty was estimated through the Edmonton Frail Scale (EFS). Demographic and clinical data, comorbidity index, and laboratory parameters were recorded. A 29-month follow-up was conducted on mortality, including hospitalization, and visits to hospital emergency services in the first 12 months of this period. Results: According to the EFS, 82 patients (29.6%) were frail, 53 (19.1%) were vulnerable, and 142 (51.3%) were non-frail. During follow-up, 58.5% frail patients, 30.2% vulnerable, and 16.2% non-frail ones died (p < .005). In the analysis of survival using an adjusted Cox model, a higher hazard of mortality was observed in frail than in non-frail patients (HR 2.34; 95% CI 1.39-3.95; p = .001). During follow-up the hospitalization rate was 852 episodes/1000 patient-years for frail patients, 784 episodes/1000 patient-years for vulnerable patients, and 417 episodes/1000 patient-years for non-frail patients (p = .0005). The incidence ratio of visits to emergency services was 3216, 1735, and 1545 visits/1000 patient-years for each group (p < .001). Conclusions: Hemodialysis patients present high frailty prevalence. Frailty is associated with poor short-term outcomes and higher rates of mortality, visits to hospital emergency services, and hospitalization.
Subject(s)
Frailty/epidemiology , Renal Dialysis/adverse effects , Renal Insufficiency, Chronic/complications , Aged , Emergency Service, Hospital/statistics & numerical data , Female , Frail Elderly/statistics & numerical data , Frailty/diagnosis , Frailty/etiology , Geriatric Assessment , Hospitalization/statistics & numerical data , Humans , Longitudinal Studies , Male , Middle Aged , Prevalence , Prospective Studies , Renal Insufficiency, Chronic/mortality , Renal Insufficiency, Chronic/therapy , Survival AnalysisABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Aged , Frail Elderly/statistics & numerical data , Renal Dialysis , Prognosis , Renal Insufficiency, Chronic/epidemiology , Frailty/epidemiology , Follow-Up Studies , Frailty/mortality , Sarcopenia/complicationsSubject(s)
Diabetic Foot/epidemiology , Diabetic Nephropathies/epidemiology , Disease Management , Kidney Failure, Chronic/epidemiology , Aged , Cardiovascular Agents/therapeutic use , Comorbidity , Diabetic Foot/therapy , Diabetic Nephropathies/prevention & control , Dyslipidemias/epidemiology , Female , Glycated Hemoglobin/analysis , Guideline Adherence , Humans , Hypertension/epidemiology , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Kidney Failure, Chronic/prevention & control , Male , Middle Aged , Patient Compliance , Retrospective Studies , Secondary Prevention , Smoking/epidemiologySubject(s)
Humans , Light Coagulation , Laser Therapy , Diabetic Nephropathies , Diabetes Mellitus, Type 2ABSTRACT
Fundamento y objetivo: La retinopatía diabética es una complicación microvascular de la diabetes mellitus cuya prevalencia está estrechamente relacionada con la presencia de nefropatía y la hipertensión. Los objetivos fueron estudiar qué factores clínicos y farmacológicos se relacionan con una mayor necesidad de fotocoagulación láser en pacientes con nefropatía y retinopatía diabética y, en segundo lugar, determinar las características diferenciales entre ambos subgrupos de pacientes diabéticos tipo 2 según si/no hubieran recibido fotocoagulación láser. Pacientes y métodos: Estudio descriptivo transversal de 63 pacientes seguidos en consulta de Nefropatía Diabética. A los pacientes se les dividió en 2 grupos según hubiesen recibido o no previamente fotocoagulación. En cada subgrupo se estudiaron variables de tipo demográfico, antropométrico, analítico, factores de riesgo cardiovascular y tratamiento que recibían los pacientes para el control de la hipertensión arterial, diabetes u otras enfermedades asociadas. Resultados: Se observó que el grupo que había recibido fotocoagulación tenía más años de evolución de la diabetes, más antecedentes de enfermedad cardiovascular y un aclaramiento de creatinina inferior. Asimismo, el porcentaje de pacientes tratados con carvedilol era significativamente superior en el subgrupo que no había recibido fotocoagulación, mientras que el porcentaje de pacientes tratados con betabloqueantes era significativamente superior en el subgrupo que sí la había recibido, no observándose diferencias en el grado de control de la tensión arterial. Conclusiones: Los factores clínicos y farmacológicos relacionados con una mayor necesidad de fotocoagulación fueron el tiempo de evolución de la diabetes, la historia previa de enfermedad cardiovascular, el grado de insuficiencia renal y el tratamiento con betabloqueantes (AU)
Background and objetive: Diabetic retinopathy is a microvascular complication of diabetes mellitus whose prevalence is closely related to the presence of nephropathy and hypertension. The aim was to study clinical and pharmacological factors that are associated with an increased need for laser photocoagulation in patients with diabetic nephropathy and retinopathy. Patients and methods: Cross sectional study of 63 patients followed in the Diabetic Nephropathy consultation. Patients were divided into 2 groups according to whether or not previously have received photocoagulation. In each subgroup were studied demographic variables, anthropometric, laboratory, cardiovascular risk factors and treatment received by each patient for the control of hypertension, diabetes and others diseases. Results: We observed that the group had received photocoagulation had more years of diabetes evolution, more history of cardiovascular disease and a lower creatinine clearance. Similary, the percentage of patients treated with carvedilol was significantly higher in the subgroup who had not received photocoagulation while the percentage of patients treated with beta-blockers was significantly higher in the subgroup that received photocoagulation; no significant differences was observed in the degree of control blood pressure. Conclusions: Clinical and pharmacological factors related to the requirements of laser photocoagulation were years of diabetes evolution, history of cardiovascular disease, the stage of kidney disease and the treatment with beta-blokers (AU)
Subject(s)
Humans , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/therapy , Light Coagulation/methods , Cross-Sectional Studies , Diabetic Retinopathy/epidemiology , Laser TherapyABSTRACT
BACKGROUND AND OBJECTIVE: Diabetic retinopathy is a microvascular complication of diabetes mellitus whose prevalence is closely related to the presence of nephropathy and hypertension. The aim was to study clinical and pharmacological factors that are associated with an increased need for laser photocoagulation in patients with diabetic nephropathy and retinopathy. PATIENTS AND METHODS: Cross sectional study of 63 patients followed in the Diabetic Nephropathy consultation. Patients were divided into 2 groups according to whether or not previously have received photocoagulation. In each subgroup were studied demographic variables, anthropometric, laboratory, cardiovascular risk factors and treatment received by each patient for the control of hypertension, diabetes and others diseases. RESULTS: We observed that the group had received photocoagulation had more years of diabetes evolution, more history of cardiovascular disease and a lower creatinine clearance. Similarly, the percentage of patients treated with carvedilol was significantly higher in the subgroup who had not received photocoagulation while the percentage of patients treated with beta-blockers was significantly higher in the subgroup that received photocoagulation; no significant differences was observed in the degree of control blood pressure. CONCLUSIONS: Clinical and pharmacological factors related to the requirements of laser photocoagulation were years of diabetes evolution, history of cardiovascular disease, the stage of kidney disease and the treatment with beta-blockers.
Subject(s)
Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/complications , Diabetic Retinopathy/surgery , Laser Coagulation/statistics & numerical data , Aged , Antihypertensive Agents/therapeutic use , Atherosclerosis/epidemiology , Cardiovascular Agents/therapeutic use , Cardiovascular Diseases/epidemiology , Comorbidity , Cross-Sectional Studies , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/epidemiology , Diabetic Nephropathies/epidemiology , Diabetic Retinopathy/complications , Diabetic Retinopathy/epidemiology , Female , Humans , Hyperlipidemias/drug therapy , Hyperlipidemias/epidemiology , Hypertension/drug therapy , Hypertension/epidemiology , Hypoglycemic Agents/therapeutic use , Hypolipidemic Agents/therapeutic use , Insulin/therapeutic use , Male , Middle Aged , Recurrence , Risk Factors , Smoking/epidemiologyABSTRACT
BACKGROUND: Decreased 25 hydroxyvitamin D serum levels have been related to an increase in cardiovascular morbility and mortality in both general population and chronic kidney disease patients. The aim of this study was to evaluate the relationship between 25 hydroxyvitamin D serum level, cardiovascular risk factors and previous established cardiovascular disease in a group of patients with advanced chronic kidney disease. MATERIAL AND METHODS: We performed a cross-sectional observational study in a cohort of 171 stage 4 and 5 chronic kidney disease outpatients seen in our predialysis clinic, mean age 64.16 +/- 13 years, 59.6% were men, 64.3% had diabetes, 47.3% had obesity, 46.8% had previous cardiovascular disease. 25 hydroxyvitamin D and 1-25 dihydroxyvitamin D were measured, we also determined other routine biochemical parameters. All subjects underwent an echocardiogram and 24 hours ambulatory blood pressure monitoring was also performed. RESULTS: Mean 25 hydroxyvitamin D levels were 22.1 +/- 13 ng/mL, only 18.7% of the patients had adequate levels, levels were insufficient in 58.5% of the patients and deficient in 22.8% of them. Low 25 hydroxyvitamin D levels were significantly related with age, diabetes, female gender, obesity, MDRD glomerular filtration rate and previous cardiovascular disease. Pulse pressure was the Ambulatory Blood Pressure Monitoring parameter that was better correlated with 25 hydroxyvitamin D levels. We could not find any association between vitamin D levels and other bone and mineral metabolism parameters. No relationship was seen between low vitamin D levels and left ventricular hypertrophy. On multivariate analysis lower levels of 25 hydroxyvitamin D were independently associated with female gender, previous cardiovascular disease, MDRD4-GFR and higher pulse pressure. CONCLUSIONS: Our study confirm a high prevalence of 25 hydroxyvitamin D insufficiency and deficiency in advanced chronic kidney disease patients, this was associated with the presence of cardiovascular risk markers and previous established cardiovascular disease. However we could not see any relationship with left ventricular hypertrophy which is a known predictor of future cardiovascular events in this population.